ArticleFrontiers in immunology2026
Efficacy and safety of secondary induction radiotherapy in locally advanced resectable esophageal squamous cell carcinoma with poor responses to neoadjuvant immunochemotherapy: a retrospective study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Multiple prospective trials have validated the efficacy and safety of neoadjuvant immunochemotherapy (nICT) in resectable esophageal squamous cell carcinoma (ESCC), yet patients with stable disease (SD) or progressive disease (PD) following nICT have limited benefit and are at risk for suboptimal surgical and pathological outcomes. The secondary induction radiotherapy prior surgery may represent a potential therapeutic strategy in this setting. Methods: We conducted a retrospective study involving 23 patients with locally advanced, resectable ESCC who demonstrated poor response to nICT (19 with SD and 4 with PD). All patients subsequently received secondary induction radiotherapy via intensity-modulated techniques or tomotherapy (median dose, 41.4 Gy). The primary endpoint was the rate of R0 resection. The secondary endpoints included pathological complete response (pCR), major pathological response (MPR), the objective response rate (ORR), the disease control rate (DCR), tumor downstaging, and treatment-related adverse events (TREAs). Results: Among the 23 patients (median age, 63 years; 82.6% male), 30.4%, 60.9%, and 8.7% had clinical stages II, III, and IVa disease, respectively. Following secondary induction radiotherapy, 4 patients (17.4%) achieved a complete response (CR), and 8 (34.8%) achieved a partial response, yielding an ORR of 52.2% and a DCR of 100%. All patients underwent resection, with an R0 resection rate of 100%. MPR was achieved in 43.5% of patients, and pCR was achieved in 21.7%. Clinical downstaging occurred in 60.9% of patients, and pathological downstaging occurred in 69.6%. The median interval from the end of radiotherapy to surgery was 48 days. Grade 3-4 surgical complications occurred in 8.7% of the patients. Radiation-related grade 3-4 adverse events included myelosuppression in 13.0% and gastrointestinal symptoms in 8.7% of the patients. Conclusions: In patients with resectable ESCC and a poor response to nICT, secondary induction radiotherapy was associated with encouraging surgical and pathological outcomes and an acceptable safety profile. Prospective studies are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.